RATIONALE: Guanfacine is an alpha2-adrenergic receptor agonist that has been shown to have beneficial effects on working memory and attentional functions in monkeys and in patients with attention deficit hyperactivity disorder. OBJECTIVES: The aim of this study was to further investigate the cognitive-enhancing properties of guanfacine using an established battery of tasks measuring executive and memory functions. METHODS:Sixty healthy male volunteers were randomised into three groups. Cognitive testing was performed from +2 to +4 h after double-blind administration of a single oral dose of 1 or 2 mg of guanfacine or placebo. RESULTS:Systolic blood pressure was significantly reduced by both doses of guanfacine at the end of the testing session. There were no statistically significant effects on any of the cognitive measures. Two trend effects were observed with poorer performance on digit span backward and slower 'Go' reaction times after guanfacine. CONCLUSION: This study found no improvement of prefrontal memory or executive functions after guanfacine. Negative effects on blood pressure and trend effects on digit span backward and go reaction time indicate a mild sedative effect of guanfacine at these doses, possibly via mechanisms of autoreceptor down-regulation.
RCT Entities:
RATIONALE: Guanfacine is an alpha2-adrenergic receptor agonist that has been shown to have beneficial effects on working memory and attentional functions in monkeys and in patients with attention deficit hyperactivity disorder. OBJECTIVES: The aim of this study was to further investigate the cognitive-enhancing properties of guanfacine using an established battery of tasks measuring executive and memory functions. METHODS: Sixty healthy male volunteers were randomised into three groups. Cognitive testing was performed from +2 to +4 h after double-blind administration of a single oral dose of 1 or 2 mg of guanfacine or placebo. RESULTS: Systolic blood pressure was significantly reduced by both doses of guanfacine at the end of the testing session. There were no statistically significant effects on any of the cognitive measures. Two trend effects were observed with poorer performance on digit span backward and slower 'Go' reaction times after guanfacine. CONCLUSION: This study found no improvement of prefrontal memory or executive functions after guanfacine. Negative effects on blood pressure and trend effects on digit span backward and go reaction time indicate a mild sedative effect of guanfacine at these doses, possibly via mechanisms of autoreceptor down-regulation.
Authors: P Jäkälä; J Sirviö; M Riekkinen; E Koivisto; K Kejonen; M Vanhanen; P Riekkinen Journal: Neuropsychopharmacology Date: 1999-02 Impact factor: 7.853
Authors: Monique Ernst; Alane S Kimes; Edythe D London; John A Matochik; Dana Eldreth; Satya Tata; Carlo Contoreggi; Michelle Leff; Karen Bolla Journal: Am J Psychiatry Date: 2003-06 Impact factor: 18.112
Authors: Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-07-06 Impact factor: 5.067
Authors: Neil Easton; Yasmene B Shah; Fiona H Marshall; Kevin C Fone; Charles A Marsden Journal: Psychopharmacology (Berl) Date: 2006-10-03 Impact factor: 4.530
Authors: Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Trevor W Robbins; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2006-04-27 Impact factor: 4.530
Authors: Andrea Bari; Dawn M Eagle; Adam C Mar; Emma S J Robinson; Trevor W Robbins Journal: Psychopharmacology (Berl) Date: 2009-04-30 Impact factor: 4.530